Cargando…

Case Report: Successful Management of a Refractory Plasmablastic Lymphoma Patient With Tislelizumab and Lenalidomide

Plasmablastic lymphoma (PBL) is a rare and aggressive hematological malignancy. PBL commonly occurs in immune incompetent patients, such as those with human immunodeficiency virus (HIV), post-transplant status, or immunosenescence. Given its rarity, there is no specific standard treatment for PBL. H...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheng, Lili, Song, Qi, Liu, Mengke, Wang, Yan, Yi, Hongmei, Qian, Ying, Xu, Pengpeng, Cheng, Shu, Wang, Chaofu, Wang, Li, Zhao, Weili
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8312258/ https://www.ncbi.nlm.nih.gov/pubmed/34322131 http://dx.doi.org/10.3389/fimmu.2021.702593

Ejemplares similares

P1240: ANTI-PD-1-ANTIBODY (TISLELIZUMAB) COMBINED WITH DEACETYLASE INHIBITOR (CHIDAMIDE), LENALIDOMIDE AND ETOPOSIDE FOR THE TREATMENT OF REFRACTORY/RELAPSED EXTRANODAL NATURAL KILLER/T CELL LYMPHOMA, NASAL
por: Zhang, L., et al.
Publicado: (2022)

Bortezomib, Lenalidomide and Dexamethasone Combination Induced Complete Remission in Relapsed/Refractory Plasmablastic Lymphoma: Case Report of a Potential Novel Treatment Approach
por: Sabry, Waleed, et al.
Publicado: (2022)

Primary refractory plasmablastic lymphoma: A precision oncology approach
por: Witte, Hanno M., et al.
Publicado: (2023)

Oncogenic Mutations and Tumor Microenvironment Alterations of Older Patients With Diffuse Large B-Cell Lymphoma
por: Zhu, Yue, et al.
Publicado: (2022)

Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis
por: Song, Yuqin, et al.
Publicado: (2022)

Hepatitis B virus‐associated follicular lymphoma presents T‐cell inflamed phenotype and response to lenalidomide
por: Wang, Nan, et al.
Publicado: (2021)

Tislelizumab-related enteritis successfully treated with adalimumab: A case report
por: Chen, Na, et al.
Publicado: (2022)

Plasmablastic plasma cell myeloma mimicking plasmablastic lymphoma
por: Choi, Qute, et al.
Publicado: (2010)

BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma
por: Raghunandan, Sharmila, et al.
Publicado: (2023)

Tumor Flare Reaction in a Classic Hodgkin Lymphoma Patient Treated With Brentuximab Vedotin and Tislelizumab: A Case Report
por: Zhu, Chunting, et al.
Publicado: (2022)

Plasmablastic lymphoma in Malawi
por: Zuze, Takondwa, et al.
Publicado: (2018)

Orbital plasmablastic lymphoma
por: Bloch, Edward, et al.
Publicado: (2017)

Plasmablastic lymphoma: An update
por: Bailly, Jenique, et al.
Publicado: (2022)

Case Report: First Occurrence of Plasmablastic Lymphoma in Activated Phosphoinositide 3-Kinase δ Syndrome
por: Yin, Zexi, et al.
Publicado: (2021)

Case Report: Clinical Responses to Tislelizumab as a First-Line Therapy for Primary Hepatocellular Carcinoma With B-Cell Indolent Lymphoma
por: Li, Qijun, et al.
Publicado: (2021)

Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trial
por: Ding, Kaiyang, et al.
Publicado: (2023)

P1233: PRIMARY REFRACTORY PLASMABLASTIC LYMPHOMA: A PRECISION ONCOLOGY APPROACH
por: Witte, H., et al.
Publicado: (2022)

Case Report: Life-threatening pancytopenia with tislelizumab followed by cerebral infarction in a patient with lung adenocarcinoma
por: Gu, Hang-Yu, et al.
Publicado: (2023)

Primary leptomeningeal plasmablastic lymphoma
por: Mathews, Marlon S., et al.
Publicado: (2011)

Plasmablastic lymphoma: current perspectives
por: Lopez, Andres, et al.
Publicado: (2018)

Tislelizumab for cervical cancer: A retrospective study and analysis of correlative blood biomarkers
por: Zheng, Xiaojing, et al.
Publicado: (2023)

Pathological complete response to neoadjuvant tislelizumab plus chemotherapy in stage IIIB small cell lung cancer: A case report and literature review
por: Zhou, Nan, et al.
Publicado: (2023)

First Occurrence of Plasmablastic Lymphoma in Adenosine Deaminase-Deficient Severe Combined Immunodeficiency Disease Patient and Review of the Literature
por: Migliavacca, Maddalena, et al.
Publicado: (2018)

Treatment of refractory MALT lymphoma by lenalidomide plus bendamustine: A case report
por: Zhou, Zhencang, et al.
Publicado: (2022)

Neoadjuvant tislelizumab combined with chemotherapy in locally advanced oral or oropharyngeal squamous cell carcinoma: a real−world retrospective study
por: Wu, Wen-Jie, et al.
Publicado: (2023)

Daratumumab, Lenalidomide, and Dexamethasone (DRD), an Active Regimen in the Treatment of Immunosuppression-Associated Plasmablastic Lymphoma (PBL) in the Setting of Gorham's Lymphangiomatosis: Review of the Literature
por: Lee, Matthew, et al.
Publicado: (2022)

Case Report: THSD7A-Positive Membranous Nephropathy Caused by Tislelizumab in a Lung Cancer Patient
por: Chen, Minjiang, et al.
Publicado: (2021)

Plasmablastic Lymphoma or Plasmablastic Myeloma: A Case of Post-Transplant Lymphoproliferative Disorder
por: Ramadas, Poornima, et al.
Publicado: (2021)

IgE+ plasmablasts predict the onset of clinical allergy
por: Simonin, Elisabeth M., et al.
Publicado: (2023)

Case Report: Bortezomib Plus CDOP Followed by Sequential Autologous Hematopoietic Stem Cell Transplantation and Lenalidomide-Based Maintenance Therapy in Plasmablastic Lymphoma
por: Cai, Jiao, et al.
Publicado: (2021)

Plasmablastic lymphoma mimicking orbital cellulitis
por: Barkhuysen, Richard, et al.
Publicado: (2008)

Plasmablastic Lymphoma Mimicking Acute Pancreatitis
por: Inayat, Faisal, et al.
Publicado: (2016)

Plasmablastic Lymphoma: A Systematic Review
por: Castillo, Jorge J., et al.
Publicado: (2011)

Plasmablastic lymphoma: one or more tumors?
por: Pileri, Stefano A., et al.
Publicado: (2021)

Plasmablastic lymphoma masked by hidradenitis suppurativa
por: Preis, Sarah, et al.
Publicado: (2022)

Relapsed/refractory classical Hodgkin lymphoma effectively treated with low-dose decitabine plus tislelizumab: A case report
por: Ding, Xiao-Sheng, et al.
Publicado: (2021)

PiggyBac-Generated CAR19-T Cells Plus Lenalidomide Cause Durable Complete Remission of Triple-Hit Refractory/Relapsed DLBCL: A Case Report
por: Li, Chenggong, et al.
Publicado: (2021)

Origin and Function of Circulating Plasmablasts during Acute Viral Infections
por: Fink, Katja
Publicado: (2012)

The Janus face of proliferating plasmablasts in dengue and COVID-19 infections
por: Nayak, Priya, et al.
Publicado: (2023)

Gut-Homing Conventional Plasmablasts and CD27(−) Plasmablasts Elicited after a Short Time of Exposure to an Oral Live-Attenuated Shigella Vaccine Candidate in Humans
por: Toapanta, Franklin R., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_pfcopenfpkogk52q2n63fq9m05